Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 1,786 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,786 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $18.74, for a total value of $33,469.64. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,360,206.08. This represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX traded down $0.03 during trading hours on Friday, hitting $18.47. The company’s stock had a trading volume of 471,766 shares, compared to its average volume of 541,313. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $19.71. The business’s 50-day moving average is $16.47 and its two-hundred day moving average is $15.75. The company has a market capitalization of $1.01 billion, a PE ratio of -8.25 and a beta of -0.78.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BCAX. HC Wainwright reissued a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Citizens Jmp began coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued a “market perform” rating and a $31.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently made changes to their positions in BCAX. T. Rowe Price Investment Management Inc. increased its position in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after purchasing an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $44,484,000. Vestal Point Capital LP boosted its stake in shares of Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $27,265,000. Finally, State Street Corp grew its holdings in shares of Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.